Sanofi

Q3 2026 13F-HR Holdings

Location
Paris, I0
Holdings as of
9/30/2026
Date filed
11/5/2026
Form type
13F-HR
Num holdings
16
Total value ($000)
$629,868
Net value change ($000)
+95,826 (17.9%)
New positions
6
Sold out positions
0
Turnover %
21.8%
Sector allocation + QoQ delta (equities-only)
Prev filing: 7/28/2026 Next filing: — SEC filing

Snapshot: Change Analysis

Compared to Q2 2026
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
Korsana Biosciences 63,808 NEW
Electra Therapeutics Inc 27,697 NEW
Attovia Therapeutics Inc 18,560 NEW
First Tracks Biotherapeutics Inc. 12,592 76.1%
Latigo Biotherapeutics Inc 11,235 NEW
NVAX 9,564 14.8%
Scribe Therapeutics 9,203 NEW
SABS 6,969 NEW
Odyssey Therapeutics Inc. 6,953 18.7%
INBX 6,172 5.6%
Top Reduces (Value $000, Stocks/ETFs)
MGTX -30,616 -18.6%
MPLT -23,394 -71.6%
ANAB -14,169 -25.5%
AGMB -5,233 -14.5%
IMRX -2,424 -17.9%
QTTB -1,091 -35.1%
Instrument mix + QoQ Δ (ex-options)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type